Peptic Ulcer Hemorrhage
3
Pipeline Programs
5
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
3100%
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Livzon PharmaceuticalChina - Zhuhai
2 programs1
1
IlaprazolePhase 3Small Molecule1 trial
IlaprazolePhase 2Small Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Livzon PharmaceuticalIlaprazole
PfizerPantoprazole
Livzon PharmaceuticalIlaprazole
Clinical Trials (3)
Total enrollment: 869 patients across 3 trials
Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
Start: Oct 2014Est. completion: Apr 2015540 patients
Phase 3Completed
Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage
Start: Apr 2001Est. completion: Jan 2003149 patients
Phase 3Completed
IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
Start: Feb 2014Est. completion: Jul 2014180 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.